npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers445
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer224
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer186
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?160
International survey on invasive lobular breast cancer identifies priority research questions149
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab111
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer110
Biological correlates associated with high-risk breast cancer patients identified using a computational method109
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab96
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer89
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment82
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women81
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer81
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients73
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells72
Immunotherapy for early triple negative breast cancer: research agenda for the next decade68
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors62
Breastfeeding attributable fraction of triple negative breast cancer in the US58
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events56
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models53
Circulating tumor DNA validity and potential uses in metastatic breast cancer51
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays50
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer49
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer48
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer46
Temporal evolution of breast cancer brain metastases treatments and outcomes45
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases43
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions40
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial39
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice39
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)39
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer39
Survival outcomes after omission of surgery for ductal carcinoma in situ39
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis38
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer37
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)37
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer34
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature34
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors33
Kataegis in clinical and molecular subgroups of primary breast cancer32
Understanding metastasis mixed-treatment responses through genomic analyses32
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer31
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling31
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification30
Is conservative management of ductal carcinoma in situ risky?30
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center30
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer29
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment29
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment29
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models29
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program28
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin28
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer28
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201628
Oncogene-mediated metabolic gene signature predicts breast cancer outcome27
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer27
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance26
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer26
Large language model (ChatGPT) as a support tool for breast tumor board25
Cook and Move for Your Life, an eHealth intervention for women with breast cancer25
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer24
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 23
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial22
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study22
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer22
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy22
Prognostic value of structural variants in early breast cancer patients21
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief21
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies21
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models21
A systematic review of determinants of breast cancer risk among women with benign breast disease21
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer20
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis20
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis20
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers20
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer19
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer19
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women19
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer18
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer18
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study18
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation18
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women17
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer17
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence17
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape17
Subclonal heterogeneity and evolution in breast cancer17
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy17
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer16
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer16
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response16
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer16
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention16
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer16
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib15
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Proteogenomic characterization of invasive breast tumors in young women15
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study15
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer15
Racial discrimination among women seeking breast cancer care15
Plasma C-peptide mammographic features and risk of breast cancer15
Post-diagnosis weight trajectories and mortality among women with breast cancer15
Artificial intelligence in breast pathology – dawn of a new era15
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer15
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination14
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression14
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial14
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer14
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer14
Genomic landscape of breast cancer in elderly patients14
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer14
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer14
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics14
Advancing equitable access to innovation in breast cancer14
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer14
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials14
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer14
0.10417103767395